Rheumatoid arthritis (RA) is a common chronic condition characterized by uncertain disease progression and an unpredictable course of exacerbations and remissions. Approximately 1–3% of the population in Western countries is affected by RA (1). Various interventions may alleviate its course, and patients come into contact with a large number and variety of health professionals. For many patients, pain, disability, deformity, and reduced quality of life persist in spite of treatment. There is room for new approaches to enhance current treatment effectiveness. Patient education is one such approach that is thought to be beneficial in helping patients cope with their disease and cooperate with its complex management (2,3). As with other chronic diseases, there is no cure for most types of arthritis, including RA. Furthermore, the disease course is often unpredictable and the symptoms that patients experience can vary from day to day or even from hour to hour. Because of the nature of pain and disability, the partial and inconsistent effects of treatment, and the unpredictability people with arthritis face on a daily basis, patient education programs have become a complement to traditional medical treatment (4). Thus, patient education programs have given people with arthritis the strategies and the tools necessary to make daily decisions to cope with the disease (5,6). Patient education has been defined as “any set of planned educational activities designed to improve patients health behaviors and/or health status” (7). Lorig has further stated “the purpose of patient education is to maintain or improve health, or, in some cases, to slow deterioration” (7). The focus of arthritis patient education programs is to teach patients to adjust their daily activities as dictated by disease symptoms. In other words, in addition to teaching patients what they should do, patients are also instructed on how to approach situations and to make adjustments that are appropriate for each individual and his or her own needs. There has been increasing research in the field of patient education, and major reviews of published studies have been conducted on the value of education in general (8) and, more recently, on education in arthritis (5,6,9,10). Two reviews on arthritis patient education reported combined effect estimates on main outcome measures, such as pain, functional disability, and psychological outcomes (9,10). Hawley reviewed 34 rheumatic disease patient education clinical trials performed between 1985 and 1995 (9). She reported average effect sizes for treatment groups compared with nonintervention controls for RA patient pain, functional ability, and depression at postintervention of 0.13, –0.16, and 0.01, respectivley; effect sizes for osteoarthritis (OA) patient pain, functional ability, and depression at postintervention were 0.44, 0.28, and 0.56, respectively (confidence intervals were not reported). These data show a trend to greater improvement for OA compared with RA patients (9). Superio-Cabuslay et al compared the effects of 19 patient education trials and 28 nonsteroidal antiinflammatory drug trials between 1966 and 1993 among patients with OA and RA (10). They found an average effect size for treatment compared with nonintervention controls for RA patient pain and funcThis article is a summary of a Cochrane systematic review: Riemsma R, Kirwan J, Taal E, Rasker J. Patient education for adults with rheumatoid arthritis. Cochrane Database Syst Rev 2002;(3):CD003688. An editorial discussing the main results of the review has been published: Riemsma RP, Taal E, Kirwan JR, Rasker JJ. Patient education programmes for adults with rheumatoid arthritis [editorial]. BMJ 2002;325:558–9. The results of a Cochrane review can be interpreted differently, depending on people’s perspectives and circumstances. Please consider the conclusions presented carefully. They are the opinions of review authors, and are not necessarily shared by the Cochrane Collaboration. The views expressed in this report are those of the authors and not necessarily those of the Dutch Arthritis Association. Any errors are the responsibility of the authors. Supported by a grant from the Dutch Arthritis Association. Robert P. Riemsma, PhD: Centre for Reviews and Dissemination, University of York, York, United Kingdom; Erik Taal, PhD: University of Twente, Enschede, The Netherlands; John R. Kirwan, BSc, MD: Bristol Royal Infirmary, Bristol, United Kingdom; Johannes J. Rasker, MD, PhD: University of Twente and Medisch Spectrum Twente, Enschede, The Netherlands. Address correspondence to Robert P. Riemsma, PhD, Centre for Reviews and Dissemination, University of York, York, YO10 5DD, UK. E-mail: rpr1@york.ac.uk. Submitted for publication July 4, 2003; accepted in revised form November 30, 2003. Arthritis & Rheumatism (Arthritis Care & Research) Vol. 51, No. 6, December 15, 2004, pp. 1045–1059 DOI 10.1002/art.20823 © 2004, American College of Rheumatology